Literature DB >> 11790229

Research evaluation and prospective diagnosis of dementia with Lewy bodies.

Oscar L Lopez1, James T Becker, Daniel I Kaufer, Ronald L Hamilton, Robert A Sweet, William Klunk, Steven T DeKosky.   

Abstract

OBJECTIVE: To evaluate the relative merits of recently developed criteria for dementia with Lewy bodies (DLBs) in a longitudinal study of dementia.
DESIGN: The diagnosis of DLBs was used in combination with other clinical diagnosis. Patients were classified primarily based on the NINCDS-ADRDA (National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association) clinical criteria for probable or possible Alzheimer disease, or with other disease process that can cause dementia (eg, Parkinson disease), and secondarily according to the consensus guidelines for DLBs. This "double" clinical diagnosis was implemented to capture different pathological entities. The neuropathological diagnosis of Lewy bodies was made with monoclonal antibodies against alpha-synuclein.
SETTING: Multidisciplinary research clinic.
RESULTS: Prospective application of the consensus guidelines for DLBs from January 1, 1997, to September 29, 2000, identified 11 patients having the diagnosis of probable DLBs and 35 having possible DLBs. The diagnosis of probable or possible DLBs was associated with probable Alzheimer disease in 34 patients, with possible Alzheimer disease in 5 patients, with Parkinson disease in 2 patients, and with other disease processes in 2 patients. Three patients were diagnosed as having probable DLBs alone. An autopsy was performed in 26 of the cases who were clinically examined during the study period. Cortical Lewy bodies were identified in 13 cases; 4 had had premortem diagnosis of DLBs (sensitivity, 30.7%; specificity, 100%).
CONCLUSIONS: The prospective validation of the clinical criteria for DLBs showed poor accuracy in this series. We believe that current criteria for DLBs are useful when DLBs occur in isolation, but have low sensitivity when Lewy bodies coexist with the pathological abnormalities of Alzheimer disease.

Entities:  

Mesh:

Year:  2002        PMID: 11790229     DOI: 10.1001/archneur.59.1.43

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  39 in total

Review 1.  Evolution of the diagnostic criteria for degenerative and cognitive disorders.

Authors:  Oscar L Lopez; Eric McDade; Mario Riverol; James T Becker
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

2.  The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study.

Authors:  K S Benke; M C Carlson; B Q Doan; J D Walston; Q L Xue; A P Reiner; L P Fried; D E Arking; A Chakravarti; M D Fallin
Journal:  Exp Gerontol       Date:  2011-09-24       Impact factor: 4.032

Review 3.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

4.  Problems associated with biological markers of Alzheimer's disease.

Authors:  H J Frey; K M Mattila; M A Korolainen; T Pirttilä
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

5.  Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases.

Authors:  Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

Review 6.  Biomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.

Authors:  Anders Lönneborg
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

7.  Carriers of a common variant in the dopamine transporter gene have greater dementia risk, cognitive decline, and faster ventricular expansion.

Authors:  Florence F Roussotte; Boris A Gutman; Derrek P Hibar; Sarah K Madsen; Katherine L Narr; Paul M Thompson
Journal:  Alzheimers Dement       Date:  2014-12-10       Impact factor: 21.566

8.  Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease.

Authors:  D Aarsland; I Litvan; D Salmon; D Galasko; T Wentzel-Larsen; J P Larsen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

9.  Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype.

Authors:  James B Leverenz; Mark A Fishel; Elaine R Peskind; Thomas J Montine; David Nochlin; Ellen Steinbart; Murray A Raskind; Gerard D Schellenberg; Thomas D Bird; Debby Tsuang
Journal:  Arch Neurol       Date:  2006-03

Review 10.  A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease.

Authors:  Marc Wermke; Christian Sorg; Afra M Wohlschläger; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.